NGNa Guo

Na Guo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Na Guo has a total of 58 co-authors. Here are the top co-authors by number of shared publications:

  • Lei Jin

    Reproductive Medicine Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China

    2 shared publications
  • Lei Jin

    Reproductive Medicine Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    2 shared publications
  • Tao-Ran Deng

    Reproductive Medicine Center, Tongji Hospital, Tongji Medicine College, Huazhong University of Science and Technology, Wuhan, China

    2 shared publications
  • Xiang Hua

    Reproductive Medicine Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095, Jiefang Avenue, Wuhan, Hubei, PR China

    2 shared publications
  • Xiao-Qiong Yuan

    Reproductive Medicine Center, Tongji Hospital, Tongji Medicine College, Huazhong University of Science and Technology, Wuhan, China

    2 shared publications
  • Xin-Ling Ren

    Reproductive medicine center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China

    2 shared publications

Latest Publications

  • Open Access

    Extracellular Vesicles From Human Fallopian Tubes Enhance IVF Embryo Development and Contain Functional Proteins Including YWHAZ

    by Yuehan Li, Wenjing Xiong, Limin Gao, Mingwei Lv, Fei Li, Rui Long, Chang Liu, Jianbo Wei, Meng Wang, Chenlu Zhang, et al.

    Extracellular vesicles (EVs) in the mammalian oviduct constitute a key maternal regulatory system that maintains redox balance during early embryogenesis, yet their molecular cargo and functional relevance in human embryos remain poorly defined. Here, we show that human Fallopian tube‐derived EVs (oEVs) are rapidly internalized by human preimplantation embryos and improve developmental quality in vitro, increasing high‐quality Day 3 embryo formation and blastocyst development. Label‐free proteomics identified 6505 oEV proteins, with metabolic, antioxidant and stress‐response pathways strongly enriched. Cross‐reference with four independent datasets revealed a conserved protein subset shared across secretory‐phase oviduct fluid, pluripotent stem cell‐derived EVs and in‐vivo‐developed embryos; among these, YWHAZ was prioritized for functional validation because of its abundance in oEVs, its presence across embryo‐related datasets, and its known involvement in stress‐response pathways. We found that Ywhaz ‐deficient mouse embryos exhibit elevated oxidative and apoptotic stress, transcriptional signatures of impaired glutathione metabolism, and failure to survive to birth despite normal blastocyst morphology. Recombinant YWHAZ protein alone failed to enter intact embryos, whereas engineered YWHAZ‐loaded EVs were efficiently internalized and significantly reduced intracellular ROS and apoptosis, restoring redox status towards in vivo levels without compromising implantation or foetal growth. Taken together, these findings identify YWHAZ protein as a conserved vesicle‐delivered regulator of redox homeostasis and demonstrate that EV‐mediated molecular delivery can partially rescue the oxidative stress burden characteristic of in vitro embryo culture. This work provides mechanistic insight into the maternal redox support system of the oviduct and establishes a foundation for EV‐based engineering of next‐generation embryo culture strategies.


  • Open Access

    Metaphase I-arrest oocyte with agar-like zona pellucida, abandon or not abandon?

    by Juepu Zhou, Qingsong Xi, Meng Wang, Ruolin Mao, Qiyu Yang, Bingxin Ma, Na Guo, Dan Li, Limin Gao, Xiangfei Wang, et al.

    The morphological appearance of zona pellucida (ZP) is considered to be predictive of the quality of the oocytes and embryos. Agar-like ZP represents a com

  • Open Access

    Rescue in vitro maturation may increase the pregnancy outcomes among women undergoing intracytoplasmic sperm injection

    by Dan-Yu Qin, Hua-Hua Jiang, Qing-Yun Yao, Wen Yao, Xiao-Qiong Yuan, Yi Wang, Tao-Ran Deng, Yao-Yao Du, Xin-Ling Ren, Na Guo, et al.

    Introduction: To investigate whether rescue in vitro maturation (R-IVM) improves the reproductive outcomes among women undergoing intracytoplasmic sperm injection (ICSI) after one oocyte retrieved cycle.Methods: Between January 2019 and December 2020, 2602 women who underwent ICSI in the Reproductive Medicine Center of Tongji Hospital, Wuhan, China, were included in our retrospective cohort study. There were 2112 women undergoing only ICSI and 490 women with R-IVM followed by ICSI. The intermediate reproductive outcomes and pregnancy outcomes were assessed, including the number of normally fertilized embryos, number of cleaved embryos, number of good-quality embryos, number of day-3 available embryos, number of embryos cultured past day-3, number of blastocysts, number of available blastocysts, biochemical pregnancy, miscarriage, clinical pregnancy and live birth. The perinatal outcomes were also assessed, including preterm birth and birth weight. The abovementioned outcomes were also calculated for in vivo matured and R-IVM oocytes separately in women undergoing ICSI with R-IVM group.Result(s): Compared with the women who underwent only ICSI, those who underwent ICSI with R-IVM had higher numbers of MII oocytes, normally fertilized embryos, cleaved embryos, day-3 available embryos, embryos cultured past day-3, and higher oocyte maturation rate, available embryo rate than women undergoing only ICSI. Additionally, we found that women undergoing ICSI with R-IVM had an increased chance of clinical pregnancy (adjusted OR=1.50, 95% CI: 1.17–1.93) and cumulative live birth (adjusted OR=1.35, 95% CI: 1.07–1.71). After propensity score matching (PSM), the cumulative live birth rate was 60.1% for women undergoing ICSI with R-IVM versus 54.9% for women undergoing only ICSI (OR=1.24, 95% CI: 0.94–1.63). The reproductive outcomes were also significantly different when calculated for in vivo matured and R-IVM oocytes separately in women undergoing ICSI with R-IVM group. All live births from R-IVM embryos were healthy and without malformations or complications.Conclusion: R-IVM may improve the reproductive outcomes of women undergoing ICSI. It may also provide a reference for the safety of R-IVM. This study maybe support a routine application of R-IVM among patients who intend to undergo ICSI.


  • Maternal preconception phthalate metabolite concentrations in follicular fluid and neonatal birth weight conceived by women undergoing in vitro fertilization

    by Lin-Jing Wu, Xue-Mei Teng, Yang-Cheng Yao, Chong Liu, Yao-Yao Du, Tao-Ran Deng, Xiao-Qiong Yuan, Qiang Zeng, Yu-Feng Li, Na Guo


  • Role of ICSI in Non-male Factor Cycles as the Number of Oocytes Retrieved Decreases from Four to One

    by Na Guo, Xiang Hua, Yu-Feng Li, Lei Jin

    This study aimed to investigate whether intracytoplasmic sperm injection (ICSI) shows an advantage over in vitro fertilization (IVF) in non-male factor cycles as the number of oocytes retrieved decreases from four to one. We undertook a retrospective analysis of 1305 IVF/ICSI cycles of non-male factor in which four or fewer oocytes were retrieved. Comparisons were made between conventional IVF (CI) and ICSI when one, two, three or four oocyte(s) were retrieved. Primary outcomes including normal fertilization rate, proportion of embryos per obtained oocyte, cycle cancellation rate, implantation rate, clinical pregnancy rate (PR), live birth rate (LBR), cumulative PR and cumulative LBR were evaluated. The results showed that the normal fertilization rate (72.5% vs. 50.0%) and the proportion of embryos per obtained oocyte (72.5% vs. 55.0%) were significantly increased in one oocyte retrieved cycles in ICSI group as compared with CI group. However, the proportion of embryos per obtained oocyte was markedly decreased in ICSI group when three (52.3% vs. 61.3%) or four (56.9% vs. 64.0%) oocytes were retrieved. The implantation rates, clinical PRs, LBRs, cumulative PRs and cumulative LBRs in CI group were comparable to those in ICSI group when one, two, three or four oocyte(s) were retrieved. In conclusion, ICSI doesn't show advantages over IVF in low oocyte yield cycles of non-male factors, even when only one oocyte was retrieved.


  • Open Access

    Effects of cumulus cell removal time during in vitro fertilization on embryo quality and pregnancy outcomes: a prospective randomized sibling-oocyte study

    by Na Guo, Fei Yang, Qun Liu, Xinling Ren, Hua Zhao, Yufeng Li, Jihui Ai

    To investigate whether cumulus cell removal after a 3 h co-incubation of gametes can affect the outcomes of in vitro fertilization. A prospective randomized sibling-oocyte study was performed in which sibling oocytes obtained from each patient were randomly assigned to either a 3 h or 20 h group (cumulus cells removed at 3 h or 20 h after insemination, respectively). Same origin embryos (either 3 h or 20 h) were transferred. The study participants were patients < 38 years old and with infertility due to tubal factors. The study outcomes included fertilization, embryo quality, and birth status. The study enrolled 172 patients, from whom 2275 oocytes were retrieved (1139 oocytes for the 3 h group and 1136 oocytes for the 20 h group). A total of 134 patients received embryo transfers (74 patients in the 3 h group and 60 patients in the 20 h group), and there were 54 live births (32 in the 3 h group and 22 in the 20 h group). When compared with patients in the 20 h group, patients in the 3 h group produced a larger number of optimal quality embryos, but had higher rates of polyspermy and low birth weight newborns. The two groups showed no differences in their rates of normal fertilization, pregnancy, and live birth. When compared with results obtained using a traditional cumulus cell removal protocol, early cumulus cell removal has both advantages and disadvantages. Further studies, and especially long-term outcome studies on newborns, need to be performed. Current controlled trial ChiCTR-OOC-15006878